AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
100 hedge funds and large institutions have $520M invested in AMAG Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 37 reducing their positions, and 19 closing their positions.
9% more capital invested
Capital invested by funds: $478M → $520M (+$42.1M)
1.83% more ownership
Funds ownership: 113.29% → 115.12% (+1.8%)
2% more call options, than puts
Call options by funds: $3.63M | Put options by funds: $3.55M
5% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 19
2% less funds holding
Funds holding: 102 → 100 (-2)
22% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 37
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$20.2M |
| 2 |
DM
Deerfield Management
New York
|
+$8.58M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$5.37M |
| 4 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
+$3.9M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$3.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$18.4M |
| 2 |
JGC
J. Goldman & Co
New York
|
-$8.79M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.77M |
| 4 |
Goldman Sachs
New York
|
-$2.56M |
| 5 |
Millennium Management
New York
|
-$2.1M |
AMAG Hedge Fund Activity: Q2 2014 in Review
100 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q2 2014, worth a combined $520M — up 8.8% from $478M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of AMAG and 18 opened new positions — a net loss of 1 holder — while 37 trimmed existing stakes and 29 added.
The largest buyer was Broadfin Capital, adding an estimated $20.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $18.4M.
- 100 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q2 2014, down from 102 in Q1 2014.
- Funds reported $520M of AMAG Pharmaceuticals stock for Q2 2014, up 8.8% quarter-over-quarter.
- 18 funds opened new AMAG Pharmaceuticals positions in Q2 2014 and 19 closed out, a net change of -1 holder.
- The largest AMAG Pharmaceuticals buyer in Q2 2014 was Broadfin Capital, an estimated $20.2M added.
- The largest AMAG Pharmaceuticals seller in Q2 2014 was T. Rowe Price Associates, an estimated $18.4M sold.
Based on aggregated 13F filings for Q2 2014.